Category

Daily Briefs

Daily Brief Australia: Deep Yellow Ltd, QV Equities Ltd, Brainfish Pty and more

By | Australia, Daily Briefs

In today’s briefing:

  • S&P/​​​​​​​​​ASX Index Rebalance Preview: Regular & Ad Hoc Changes in June
  • QV Equities (QVE AU): 28th June Shareholder Vote
  • Surge leads self-service customer support platform Brainfish’s US$2.5M seed round | e27


S&P/​​​​​​​​​ASX Index Rebalance Preview: Regular & Ad Hoc Changes in June

By Brian Freitas

  • With the review period complete, we take a look at the potential index changes at the June rebalance as well as potential index inclusions due to M&A.
  • Timing is key for the ad hoc inclusions to the S&P/ASX 200 (AS51 INDEX) with an ad hoc inclusion being announced prior to the regular announcement.
  • Passive trackers will need to buy 1.3-27x ADV on the expected adds and have 0.8-4.7x ADV to sell on the expected deletes. Shorts have built up on the potential deletes.

QV Equities (QVE AU): 28th June Shareholder Vote

By David Blennerhassett

  • On the 12th March, Aussie-based investment plays QV Equities Ltd (QVE AU) and WAM Leaders Ltd (WLE AU)  entered into a Scheme
  • The current scrip terms are 0.739 new WAM shares per QVE share; OR A$0.989/share cash. Terms will be adjusted for updated pre-tax NTA/shares of both companies after the Scheme Meeting. 
  • The Scheme Booklet is now out, with a Scheme Meeting to be held on the 28th June. Expected implementation on the 15 July. The IE says fair & reasonable.

Surge leads self-service customer support platform Brainfish’s US$2.5M seed round | e27

By e27

  • Brainfish, an AI-powered self-service customer support platform for businesses, has raised US$2.5 million in seed funding.
  • The latest round was led by Peak XV’s Surge, with participation from Macdoch Ventures, Black Sheep Capital, existing angel Justus Hammer (CEO MadPaws), and new angels.
  • This brings its total capital to US$3.3 million.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: Rize , UOL Group and more

By | Daily Briefs, Singapore

In today’s briefing:

  • Temasek co-leads $14m round of SG agritech firm Rize
  • STI Gains 7% over Six Weeks on Net Institutional Inflow


Temasek co-leads $14m round of SG agritech firm Rize

By Tech in Asia

  • Rize, a Singapore-based agritech startup, has secured US$14 million in a series A funding round co-led by Breakthrough Energy Ventures, GenZero, Temasek, and Wavemaker Impact.
  • The company plans to use the funds to boost its presence in other markets like Indonesia and Vietnam.
  • It also aims to increase its team of agronomy experts to over 100. Rize’s platform gathers key agricultural information needed for sustainable farming.

STI Gains 7% over Six Weeks on Net Institutional Inflow

By Geoff Howie

  • On 27 May, the STI closed at 3,318.45, its highest close since August 2023.
  • STI stocks within the Real Estate Management and Development sector – Hongkong Land, City Developments and UOL Group – all booked net institutional inflow while averaging 7.1% total returns.
  • 10 Real Estate (Ex-REITs) stocks that booked most net institutional inflow since 16 April Code Mkt Cap S$M YTD ADT S$M YTD NIF S$M YTD TR % 17 April – 27 May NIF / Mkt Cap 16 April – 27 May TR % Sector.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: DS Dansuk, Shift Up and more

By | Daily Briefs, South Korea

In today’s briefing:

  • DS Dansuk: Block Deal Sale by Stonebridge Capital
  • Shift Up IPO: The Investment Case
  • Shift Up IPO – Thoughts on Valuations – Bear/Base/Bull


DS Dansuk: Block Deal Sale by Stonebridge Capital

By Douglas Kim

  • After the market close on 28 May, it was announced that Stonebridge Capital plans to conduct a block deal sale of a portion of its stake in DS Dansuk.
  • This deal involves 210,000 to 290,000 shares of DS Dansuk. The block deal price range is from 99,800 won to 101,400 won, which represents 7.06% to 8.52% discount.
  • After this second block deal, there will be further overhang concerns about additional sales of DS Dansuk by Stonebridge Capital in the coming months. 

Shift Up IPO: The Investment Case

By Arun George

  • Shift Up (462870 KS) is Korea’s leading game development studio. It is seeking to raise up to US$320 million.    
  • Shift Up now focuses only on game development and has a policy of publishing games in cooperation with global partners such as Tencent (700 HK) and Sony Corp (6758 JP)
  • The investment case rests on a stellar game development track record, several growth drivers, high profitability and cash generation.

Shift Up IPO – Thoughts on Valuations – Bear/Base/Bull

By Sumeet Singh

  • Shift Up (462870 KS) plans to raise up to US$320m in its South Korean IPO.
  • Shift Up is a South Korean games developer, which as released three games so far for the global markets.
  • We have looked at the company’s performance in our past notes. In this note, we talk about valuations.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Abeona Therapeutics , Edesa Biotech , Essa Pharma , Guess? Inc, NeuroBo Pharmaceuticals , NOW Inc, Royce Micro-Cap Trust and more

By | Daily Briefs, United States

In today’s briefing:

  • ABEO: BLA Resubmission in 2H24
  • EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo
  • EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24
  • GES: 1Q Preview: Building for the Future: Reiterate Buy, $37 PT
  • NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024
  • DNOW, Inc. – FY24 Free Cash Flow Outlook Lifted
  • Royce Microcap Trust (RMT) – Tuesday, Feb 27, 2024


ABEO: BLA Resubmission in 2H24

By Zacks Small Cap Research

  • On May 15, 2024, Abeona Therapeutics, Inc. (ABEO) announced financial results for the first quarter of 2024 and provided a business update.
  • The company is planning to resubmit the Biologics License Application (BLA) for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB) in the second half of 2024 following the receipt of a Complete Response Letter (CRL) in April 2024.
  • The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data but did request additional CMC information.

EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo

By Zacks Small Cap Research

  • On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update.
  • Edesa is planning to seek regulatory approval for a Phase 2 trial of its anti-CXCL10 mAb in patients with moderate-to-severe nonsegmental vitiligo.
  • For EB05, the company has expanded site selection activities for the Phase 3 study in acute respiratory distress syndrome (ARDS) caused by COVID-19 and has begun transitioning the day-to-day management of the trial to a new clinical research organization (CRO).

EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24

By Zacks Small Cap Research

  • On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update.
  • ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.
  • The -001 trial consists of Part A monotherapy treatment and Part B combination therapy of masofaniten plus abiraterone acetate/prednisone (Cohort 1 mHSPC or mCRPC) or with apalutamide following 12 weeks of monotherapy therapy (Cohort 2 nmCRPC).

GES: 1Q Preview: Building for the Future: Reiterate Buy, $37 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating, $37 price target and projections for Guess?
  • with the company announcing 1QFY25 (April) results after the close on Thursday.
  • We believe 1Q, which included material upgrades in the domestic retail store base, the acquisition of contemporary leader rag & bone, continued European expansion and what we believe were cautious buys from the domestic wholesale segment, will set the stage for a strong back-half and FY26, but will result, beyond further share repurchases, in limited top and bottom line upside for 1Q.

NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024

By Zacks Small Cap Research

  • On May 22, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced that preclinical data of DA-1241 in combination with semaglutide in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2024 on Thursday, June 6, 2024.
  • Two abstracts will be presented: one using the GAN diet-induced obese and biopsy-confirmed mouse model of MASH and one using the CCl4 induced liver fibrosis model.
  • The company shared some of the results that showed an additive effect on different parameters of liver health in both models, with the posters being available following the presentations.

DNOW, Inc. – FY24 Free Cash Flow Outlook Lifted

By Water Tower Research

  • The 1Q24 Whitco Supply acquisition diversified DNOW’s customer base and added new revenue opportunities in the midstream markets.
  • Management now expects FY24 revenue to increase in the mid- to high single digits range from FY23 and for adjusted EBITDA margin to be in line with FY23.
  • Management lifted its FY24 free cash flow outlook to ~$200 million from ~$150 million.

Royce Microcap Trust (RMT) – Tuesday, Feb 27, 2024

By Value Investors Club

  • RMT is a closed-end fund focused on micro-cap stocks, offering exposure to a segment not easily accessible through other investments
  • RMT has a notable performance track record and is currently trading at a discount of about 12%
  • RMT is the only closed-end fund solely dedicated to micro-cap stocks, providing a unique investment opportunity for those seeking exposure to this niche market segment

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Akeso Biopharma Inc, Jiangxi Rimag Group, Sichuan Kelun-Biotech Biopharm, China Vanke and more

By | China, Daily Briefs

In today’s briefing:

  • Is Akeso’s Sell-Off a Long Waited Opportunity or a Long Overdue Correction?
  • Pre-IPO Jiangxi Rimag Group (PHIP Updates) – Some Points Worth the Attention
  • Sichuan Kelun-Biotech Biopharm (6990.HK) – Current High Valuation Is Not Secure
  • Morning Views Asia: China Vanke


Is Akeso’s Sell-Off a Long Waited Opportunity or a Long Overdue Correction?

By Eric Wen

  • Disputable Phase III result of Akeso’s (9926 HK) flagship pipeline Ivonescimab (AK112) caused Akeso’s share price to drop 28% in three days, reaching the bottom of a year-long trading range;
  • The fundamental difference of opinions is around Ivonescimab’s global prospects against (1) Merck’s Keytruda, (2) J&J’s Rybrevant, (3) Kelun’s SKB264 and domestic prospect against (4) Innovent’s IBI305;
  • Some answers are clear while others are now. What can provide answers are (1) SKB264‘s Phase III data, and to a lesser degree (2) AK112’s head-to-head trial against Keytruda.

Pre-IPO Jiangxi Rimag Group (PHIP Updates) – Some Points Worth the Attention

By Xinyao (Criss) Wang

  • Considering the dominant position of medical imaging centers in public hospitals and challenges from other players, future development space of Rimag would be squeezed,and even will soon encounter growth bottlenecks.
  • Although Rimag turned losses into profits, we still have doubts about its future profitability due to increasing costs and potential price decline.This business may fail to bring investors decent profits.
  • Rimag’s post-investment valuation after last round financing isn’t cheap.Given the uncertainty of future revenue growth prospects and the real market space, P/S of below 3 is a more comfortable range.

Sichuan Kelun-Biotech Biopharm (6990.HK) – Current High Valuation Is Not Secure

By Xinyao (Criss) Wang

  • The imagination space and good stories for Sichuan Kelun-Biotech Biopharm (6990 HK) at this stage mainly come from SKB264. The market has higher expectations for SKB264’s clinical data on NSCLC/TNBC. 
  • The better the clinical results of SKB264 +PD1/L1, the greater the negative impact on AK112’s future expectations/market space in NSCLC. ADC +PD-1 seems more “convincing” than the logic of BsAb.
  • This July, restricted shares of major shareholders will be lifted, which may lead to big share price fluctuation if they reduce their shareholdings. Investors need not rush to be long.

Morning Views Asia: China Vanke

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: PNB Housing Finance Ltd, Indian Energy Exchange Ltd, Virtuoso Optoelectronics and more

By | Daily Briefs, India

In today’s briefing:

  • PNB Housing: Block Deal Trade Special Situations and Tactical Trade Strategy
  • Indian Energy Exchange: Do You Want to Earn a Royalty on India’s Economic Growth?
  • Virtuoso Optoelectronics Ltd- Forensic Analysis


PNB Housing: Block Deal Trade Special Situations and Tactical Trade Strategy

By Nimish Maheshwari

  • Impending block deals which generally create supply over-hang on the stock leads to a negative impact on the stock. 
  • These block deals generally include selling promoters and big funds at a price discount to its current market price. 
  • Historically, such events suggest once the block deal is done; stock reacts positively creating a Special Situation Opportunity

Indian Energy Exchange: Do You Want to Earn a Royalty on India’s Economic Growth?

By Contrarian Cashflows

  • As one of the fastest-growing economies globally, India is projected to become the third-largest economy, trailing only China and the US, by 2027.
  • Amid macroeconomic challenges worldwide, investors are eager to tap into India’s robust economic growth.
  • However, economic growth does not always correlate with equity market growth, as seen in Spain and Italy during the 1980s and 1990s, and more recently in China.

Virtuoso Optoelectronics Ltd- Forensic Analysis

By Nitin Mangal

  • Virtuoso Optoelectronics (VOEPL IN)  is a contract manufacturer company engaged into production of ACs, Lightings and other equipments. The company is renowned for supplying ACs to Voltas.
  • The company has grown sharply over the last five years and has been engaging in constant capex. However, it does struggle in converting its earnings to cash.
  • Among the forensic checks, it nets off receivables and payables/advances, the exact nature of these line items cannot be commented upon. VOEPL also faces high cost of borrowings

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Akatsuki Inc, LY , TSE Tokyo Price Index TOPIX, JTEC Corp/Osaka and more

By | Daily Briefs, Japan

In today’s briefing:

  • Akatsuki Inc (TYO 3932): A $188M Net Net Japanese Game Developer
  • Yahoo Still Falling Further Behind Amazon and Rakuten
  • Increasing Profitability to Gain Support from Overseas Investors Is a Condition for Higher Valuation
  • JTEC Corp (3446) – Facing Some Challenges over Lead Times


Akatsuki Inc (TYO 3932): A $188M Net Net Japanese Game Developer

By Altay Capital

  • Akatsuki Inc (TYO 3932) is a net-net Japanese video game developer with 10 years of profitability.
  • They’re undergoing a big transformation in an effort to better compete globally by investing enormous amounts into their core development capabilities and increasing their average budget per game 3-6x.
  • They recently formed a capital alliance with Sony (6758) and Koei Tecmo (TYO 3635) with each taking a 10% and 8% stake respectively.

Yahoo Still Falling Further Behind Amazon and Rakuten

By Michael Causton

  • LY (4689 JP)‘s Yahoo Shopping looks to be in trouble after five straight quarters of negative growth while Amazon and Rakuten move ahead.
  • Despite a revenue increase in 4Q2023, Yahoo Shopping continues to struggle with merchant fraud and a lack of a clear USP.
  • If effective integration between the many parts of LY is not forthcoming soon, the company may eventually attract demands for better synergies, as well as a stick-wielding Softbank.

Increasing Profitability to Gain Support from Overseas Investors Is a Condition for Higher Valuation

By Aki Matsumoto

  • Even after the TSE’s request for a P/B increase, it is not possible to raise valuations simply on the expectation of a P/B increase without improving profitability.
  • Most companies have cash allocation challenges. Companies with higher profitability will accumulate even more cash on hand, so higher level of shareholder return will further positively impact ROE and ROA.
  • Some of the companies that have reduced valuations include those with relatively high ROE and ROA, so there are small-cap stocks with reduced valuations and increased investment opportunities.

JTEC Corp (3446) – Facing Some Challenges over Lead Times

By Astris Advisory Japan

  • Lengthening order lead times impacting revenue recognition – Q1-3 FY6/24 results were behind expectations in our view, with sales declining 27.6% YoY.
  • Whilst a negative optic, the reason stems from lengthening lead times for shipment, given customer demands for more high-end and exacting technical requirements for custom-made products requiring more time for delivery.
  • We believe this highlights the value-added technical expertise of the company and delays in revenue recognition. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Kokusai Electric , Exedy Corp, Asia Vital Components, AU Optronics, Huafa Property Services Group, Deep Yellow Ltd, Barito Renewables Energy, Celltrion Inc, Asmedia Technology and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Kokusai Elec (6525) – The Much-Anticipated Lockup Expiry
  • Cash-Rich Exedy (7278) Sees Huge Offering Offset by Huge Buyback – Watch For Short-Term Games
  • Taiwan Top 50 ETF Rebalance Preview: Asia Vital Components (3017 TT) In Back-To-Back Inclusion?
  • Yuanta Taiwan Div+ ETF Rebalance Preview: 5 Changes as Names Move Around; US$2.35bn Round-Trip Trade
  • ASMedia GDR Early Look – Momentum Has Been Strong, and Raising Would Grow Its Cash Base Almost 6x
  • Huafa Property Services (982 HK)’s Knockout Offer
  • S&P/​​​​​​​​​ASX Index Rebalance Preview: Regular & Ad Hoc Changes in June
  • Barito Renewables Lockup Expiry – US$8bn Lockup Expiry for Largest Indonesian Market Cap Stock
  • FnGuide Top 5 Plus Index Rebalance Preview: Celltrion Could Replace KT&G
  • ASMedia GDR Offering – Well Flagged, and Momentum Has Been Strong Leading into the Offering


Kokusai Elec (6525) – The Much-Anticipated Lockup Expiry

By Travis Lundy

  • Last autumn, Kokusai Electric (6525 JP) was IPOed by KKR. The lockup expires next week, on 21 April 2024 (a Sunday). That frees up about 70% of the stock.
  • KKR’s own stake is worth about US$2.8bn. It is not clear that Applied Materials, Qatar, or the Koch Strategic Platforms stakes would be for sale (now, or near-term).
  • There is an interesting schedule of events between here and a likely offering date. It pays to pay attention to the details. 

Cash-Rich Exedy (7278) Sees Huge Offering Offset by Huge Buyback – Watch For Short-Term Games

By Travis Lundy

  • Toyota equity affiliate Aisin (7259 JP) last September said it would sell all its crossholdings. That now includes a 36.5% stake in Exedy Corp (7278 JP)
  • Today, they announced an offering of all the shares (when including the greenshoe). That is nearly ¥50bn. That is offset by a ¥15bn buyback which could reduce the offering size.
  • Games may be played, but there is considerable accretion, and Exedy will see higher float and still-high net cash.

Taiwan Top 50 ETF Rebalance Preview: Asia Vital Components (3017 TT) In Back-To-Back Inclusion?

By Brian Freitas


Yuanta Taiwan Div+ ETF Rebalance Preview: 5 Changes as Names Move Around; US$2.35bn Round-Trip Trade

By Brian Freitas

  • With the review period now complete, there could be 5 changes to the Yuanta/​P-Shares Taiwan Dividend Plus ETF in June.
  • Price changes and changes to dividend estimates have led to names dropping off the list of potential adds and deletes over the last week.
  • Constituent changes, capping and funding flows will lead to a one-way turnover of 12.7% and a one-way trade of US$1.17bn. There are 12 stocks with over 4x ADV to trade.

ASMedia GDR Early Look – Momentum Has Been Strong, and Raising Would Grow Its Cash Base Almost 6x

By Clarence Chu

  • Asmedia Technology (5269 TT) is looking to raise up to US$333m in its upcoming global depository receipts (GDRs) offering.
  • ASMedia recently announced its board’s resolution to offer between 4.3-5.3m shares in the form of GDRs, with the proceeds geared towards purchasing raw materials and machinery, R&D and working capital.
  • Similar to previous GDR listings, the deal is a long drawn out process with the firm required to jump through a number of board/shareholder/regulatory approval loops.

Huafa Property Services (982 HK)’s Knockout Offer

By David Blennerhassett

  • After entering a trading halt on the 16th May pursuant to the Takeover’s Code, property manager Huafa Property Services (982 HK) has now announced a privatisation by way of a Scheme. 
  • The cancellation price of A$0.29/share is a 30.63% to last close, a 70.59% premium over the 30-day average close, and a life-time high price. The price is final.
  • The Offeror, Zhuhai Huafa, a state-owned enterprise wholly-owned by Zhuhai SASAC, plus concert parties hold 42.63% of shares out. Clean deal.

S&P/​​​​​​​​​ASX Index Rebalance Preview: Regular & Ad Hoc Changes in June

By Brian Freitas

  • With the review period complete, we take a look at the potential index changes at the June rebalance as well as potential index inclusions due to M&A.
  • Timing is key for the ad hoc inclusions to the S&P/ASX 200 (AS51 INDEX) with an ad hoc inclusion being announced prior to the regular announcement.
  • Passive trackers will need to buy 1.3-27x ADV on the expected adds and have 0.8-4.7x ADV to sell on the expected deletes. Shorts have built up on the potential deletes.

Barito Renewables Lockup Expiry – US$8bn Lockup Expiry for Largest Indonesian Market Cap Stock

By Ethan Aw

  • Barito Renewables Energy (BREN IJ) raised around US$200m in its Indonesian IPO, after pricing at the top end at IDR780/share. Its eight-month lockup will expire on 29th May 2024.
  • Barito Renewables (BR) is Indonesia’s largest geothermal power producer, and the third-largest globally by installed capacity, as per the firm.
  • In this note, we will talk about the lock-up dynamics and updates since our last note.

FnGuide Top 5 Plus Index Rebalance Preview: Celltrion Could Replace KT&G

By Brian Freitas


ASMedia GDR Offering – Well Flagged, and Momentum Has Been Strong Leading into the Offering

By Clarence Chu

  • Asmedia Technology (5269 TT) is looking to raise up to US$335m in its global depository receipts (GDRs) offering.
  • Overall, the deal would be a relatively small one for the stock to digest at just 5.6 days of its three month ADV.
  • In this note, we run the deal through our ECM framework and comment on deal dynamics.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Industrials: DS Dansuk, Enav SpA, Norcros PLC, NOW Inc and more

By | Daily Briefs, Industrials

In today’s briefing:

  • DS Dansuk: Block Deal Sale by Stonebridge Capital
  • Enav Spa (ENAV IM) – Tuesday, Feb 27, 2024
  • Norcros – Vast opportunity and new targets revealed
  • DNOW, Inc. – FY24 Free Cash Flow Outlook Lifted


DS Dansuk: Block Deal Sale by Stonebridge Capital

By Douglas Kim

  • After the market close on 28 May, it was announced that Stonebridge Capital plans to conduct a block deal sale of a portion of its stake in DS Dansuk.
  • This deal involves 210,000 to 290,000 shares of DS Dansuk. The block deal price range is from 99,800 won to 101,400 won, which represents 7.06% to 8.52% discount.
  • After this second block deal, there will be further overhang concerns about additional sales of DS Dansuk by Stonebridge Capital in the coming months. 

Enav Spa (ENAV IM) – Tuesday, Feb 27, 2024

By Value Investors Club

  • ENAV’s stock trades at a lower multiple compared to peers in the European airport concession industry
  • Shareholder activism could potentially influence board decisions despite majority ownership by the Italian government
  • ENAV’s cash flow is expected to improve, offering a potential 15% free cash flow yield by 2025 and presents minimal downside risk with significant upside potential if it trades closer to historical valuation multiples

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Norcros – Vast opportunity and new targets revealed

By Edison Investment Research

Norcros is the UK’s leading design-led sustainable kitchen and bathroom products group. Its compelling investment case was highlighted at its May 2024 capital markets day (CMD), where its unique, asset-light, design-led model was clearly illustrated. The CMD also indicated the enormous scale of the opportunity that is available in terms of entering adjacent unaddressed markets in the UK and South Africa, as well as the potential presented by other attractive geographies. Furthermore, revised medium-term targets were introduced that should further excite investors. Our profit forecasts are unchanged, but we have raised our valuation from 246p to 251p as we have rolled forward our P/E valuation and increased our FY25 dividend estimate.


DNOW, Inc. – FY24 Free Cash Flow Outlook Lifted

By Water Tower Research

  • The 1Q24 Whitco Supply acquisition diversified DNOW’s customer base and added new revenue opportunities in the midstream markets.
  • Management now expects FY24 revenue to increase in the mid- to high single digits range from FY23 and for adjusted EBITDA margin to be in line with FY23.
  • Management lifted its FY24 free cash flow outlook to ~$200 million from ~$150 million.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: DS Dansuk, Enav SpA, Norcros PLC, NOW Inc and more

By | Daily Briefs, Industrials

In today’s briefing:

  • DS Dansuk: Block Deal Sale by Stonebridge Capital
  • Enav Spa (ENAV IM) – Tuesday, Feb 27, 2024
  • Norcros – Vast opportunity and new targets revealed
  • DNOW, Inc. – FY24 Free Cash Flow Outlook Lifted


DS Dansuk: Block Deal Sale by Stonebridge Capital

By Douglas Kim

  • After the market close on 28 May, it was announced that Stonebridge Capital plans to conduct a block deal sale of a portion of its stake in DS Dansuk.
  • This deal involves 210,000 to 290,000 shares of DS Dansuk. The block deal price range is from 99,800 won to 101,400 won, which represents 7.06% to 8.52% discount.
  • After this second block deal, there will be further overhang concerns about additional sales of DS Dansuk by Stonebridge Capital in the coming months. 

Enav Spa (ENAV IM) – Tuesday, Feb 27, 2024

By Value Investors Club

  • ENAV’s stock trades at a lower multiple compared to peers in the European airport concession industry
  • Shareholder activism could potentially influence board decisions despite majority ownership by the Italian government
  • ENAV’s cash flow is expected to improve, offering a potential 15% free cash flow yield by 2025 and presents minimal downside risk with significant upside potential if it trades closer to historical valuation multiples

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Norcros – Vast opportunity and new targets revealed

By Edison Investment Research

Norcros is the UK’s leading design-led sustainable kitchen and bathroom products group. Its compelling investment case was highlighted at its May 2024 capital markets day (CMD), where its unique, asset-light, design-led model was clearly illustrated. The CMD also indicated the enormous scale of the opportunity that is available in terms of entering adjacent unaddressed markets in the UK and South Africa, as well as the potential presented by other attractive geographies. Furthermore, revised medium-term targets were introduced that should further excite investors. Our profit forecasts are unchanged, but we have raised our valuation from 246p to 251p as we have rolled forward our P/E valuation and increased our FY25 dividend estimate.


DNOW, Inc. – FY24 Free Cash Flow Outlook Lifted

By Water Tower Research

  • The 1Q24 Whitco Supply acquisition diversified DNOW’s customer base and added new revenue opportunities in the midstream markets.
  • Management now expects FY24 revenue to increase in the mid- to high single digits range from FY23 and for adjusted EBITDA margin to be in line with FY23.
  • Management lifted its FY24 free cash flow outlook to ~$200 million from ~$150 million.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars